AIM ImmunoTech (AIM ImmunoTech) EV-to-Revenue : 49.85 (As of Apr. 28, 2024)

View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AIM ImmunoTech's enterprise value is $10.07 Mil. AIM ImmunoTech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.20 Mil. Therefore, AIM ImmunoTech's EV-to-Revenue for today is 49.85.

The historical rank and industry rank for AIM ImmunoTech's EV-to-Revenue or its related term are showing as below:

AIM' s EV-to-Revenue Range Over the Past 10 Years
Min: -150.52 Med: 71.26 Max: 474
Current: 49.85

During the past 13 years, the highest EV-to-Revenue of AIM ImmunoTech was 474.00. The lowest was -150.52. And the median was 71.26.

AIM's EV-to-Revenue is ranked worse than
77.54% of 1033 companies
in the Biotechnology industry
Industry Median: 7.66 vs AIM: 49.85

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), AIM ImmunoTech's stock price is $0.4282. AIM ImmunoTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, AIM ImmunoTech's PS Ratio for today is 107.05.

AIM ImmunoTech EV-to-Revenue Historical Data

The historical data trend for AIM ImmunoTech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech EV-to-Revenue Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

28.49

242.16

-24.07

-125.24

49.19

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-125.24	-54.67	32.95	6.28	49.19

Competitive Comparison of AIM ImmunoTech's EV-to-Revenue

For the Biotechnology subindustry, AIM ImmunoTech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's EV-to-Revenue falls into.

AIM ImmunoTech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

AIM ImmunoTech's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	10.069	/	0.202
	=	49.85

AIM ImmunoTech's current Enterprise Value is $10.07 Mil.
AIM ImmunoTech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.

AIM ImmunoTech (AMEX:AIM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

AIM ImmunoTech's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.4282	/	0.004
	=	107.05

AIM ImmunoTech's share price for today is $0.4282.
AIM ImmunoTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

AIM ImmunoTech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (AIM ImmunoTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Executives

Thomas K. Equels	director, officer: Vice Chairman of Board	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth	director	2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii	director	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal	officer: CFO	2117 SW HWY 484, OCALA FL 34473
William M Mitchell	director	2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate	officer: VP of Operations	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer	other: Medical Director	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale	officer: CFO	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli	officer: VP, Quality Control	510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander	officer: VP of Process/QualityAssurance	784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey	officer: Senior Vice President	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii	officer: CFO	23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence	director	250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli	officer: President & COO	P.O. BOX 521, NEW VERNON NJ 07976